Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy

被引：164

作者：

Cheok, MH

Evans, WE

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Univ Tennessee, Memphis, TN 38105 USA

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 02期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nrc1800

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of combination chemotherapy to cure acute lymphoblastic leukaemia (ALL) in children emerged in the 1980s as a paradigm for curing any disseminated cancer, and many of the therapeutic principles were subsequently applied to the treatment of other disseminated human cancers. Similarly, elucidation of the pharmacogenomics of ALL and its translation into new chemotherapeutic approaches might serve as a model for optimizing the treatment of other human cancers. Germline polymorphisms and gene-expression patterns in ALL cells have been linked to the toxicity and efficacy of chemotherapy for ALL and are beginning to emerge as useful clinical diagnostics.

引用

收藏

页码：117 / 129

页数：13

相关论文

共 118 条

[111] Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays [J].

Willenbrock, H ;

Juncker, AS ;

Schmiegelow, K ;

Knudsen, S ;

Ryder, LP .

LEUKEMIA, 2004, 18 (07) :1270-1277

[112] Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier [J].

Wong, SC ;

Zhang, L ;

Witt, TL ;

Proefke, SA ;

Bhushan, A ;

Matherly, LH .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (15) :10388-10394

[113] Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies [J].

Woo, MH ;

Shuster, JJ ;

Chen, C ;

Bash, RO ;

Behm, FG ;

Camitta, B ;

Felix, CA ;

Kamen, BA ;

Pui, CH ;

Raimondi, SC ;

Winick, NJ ;

Amylon, MD ;

Relling, MV .

LEUKEMIA, 2000, 14 (02) :232-237

[114] Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance [J].

Yates, CR ;

Krynetski, EY ;

Loennechen, T ;

Fessing, MY ;

Tai, HL ;

Pui, CH ;

Relling, MV ;

Evans, WE .

ANNALS OF INTERNAL MEDICINE, 1997, 126 (08) :608-+

[115] Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling [J].

Yeoh, EJ ;

Ross, ME ;

Shurtleff, SA ;

Williams, WK ;

Patel, D ;

Mahfouz, R ;

Behm, FG ;

Raimondi, SC ;

Relling, MV ;

Patel, A ;

Cheng, C ;

Campana, D ;

Wilkins, D ;

Zhou, XD ;

Li, JY ;

Liu, HQ ;

Pui, CH ;

Evans, WE ;

Naeve, C ;

Wong, LS ;

Downing, JR .

CANCER CELL, 2002, 1 (02) :133-143

[116] Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment [J].

Zaza, G ;

Cheok, M ;

Yang, WJ ;

Panetta, JC ;

Pui, CH ;

Relling, MV ;

Evans, WE .

BLOOD, 2005, 106 (05) :1778-1785

[117] Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis [J].

Zaza, G ;

Yang, WJ ;

Kager, L ;

Cheok, M ;

Downing, J ;

Pui, CH ;

Cheng, C ;

Relling, MV ;

Evans, WE .

BLOOD, 2004, 104 (05) :1435-1441

[118]

ZAZA G, 2004, THIOPURINE PATHWAY

← 3 4 5 6 7 8 9 10 11 12 →